Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia

Targeting the lncRNA DUXAP8/miR-29a/PIK3CA Network Restores Doxorubicin Chemosensitivity via PI3K-AKT-mTOR Signaling and Synergizes With Inotuzumab Ozogamicin in Chemotherapy-Resistant B-Cell Acute Lymphoblastic Leukemia

“…For chemotherapy-refractory or relapsed B-ALL patients, salvage treatment options are lacking and urgently need investigation. Currently, inotuzumab ozogamicin, an anti-CD22 antibody–drug conjugate, achieves encouraging efficacy and acceptable tolerance as a salvage treatment regimen in refractory or relapsed B-ALL patients ( 46 – 50 ). In the current study, it was further discovered that targeting lncRNA DUXAP8 and inotuzumab ozogamicin had synergistic effects in killing chemoresistant B-ALL cells.…”

Role of allogeneic haematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukaemia in the era of immunotherapy

“…The INO-VATE clinical trial revealed that the median OS was only 7.7 months in the InO group, with a 2-year OS rate of 22.8%. [51] Fujishima et al [52] reported that the median OS for InO arms was 5.8 months in r/r ALL patients. Bridging to allo-HSCT after InO may improve long-term (NCT02003612) [62] 189 Blinatumomab/ CD19 Adults with B-precursor Ph-negative r/r ALL [67] 20 for infused; 22 for ITT CNCT19 CD19-CAR-T Pediatric and adult B-ALL patients with r/r B-ALL -18 (90.0%) for infused 18 (82.0%) for ITT 100.0% for CR mOS 12.91 months for N = 20 infused mPFS 6.93 months for N = 20 infused NCT02315612 [32] 21 CNCT19 CD19-CAR-T r/r B-ALL treated children and adults, including 17 who were previously treated with CD19directed immunotherapy 100.0% 12/21 (57.0%) 9/12 (75.0%) Median remission duration: 6 months NCT01044069 [42] 83 enrolled; [69] 13 (4 pediatric and 9 adult patients infused) ChiCTR-llh-16008711 [46] 51/51 outcomes.…”

“…The INO-VATE clinical trial revealed that the median OS was only 7.7 months in the InO group, with a 2-year OS rate of 22.8%. [51] Fujishima et al [52] reported that the median OS for InO arms was 5.8 months in r/r ALL patients. Bridging to allo-HSCT after InO may improve long-term NCTO1593696 [31] 20/20 ChiCTR-llh-16008711 [46] 51/51 NCT01626495 and NCT01029366 [29] 30/30 outcomes.…”

Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: A Report of Four Cases

“…InO has drastically improved the treatment of RR-ALL. A randomized phase III clinical trial, the INO-VATE study, which included 55 Asian patients, showed that the CR/CRi (CR with incomplete hematologic recovery) rate was significantly higher than the standard of care (SoC) with intensive chemotherapy including FLAG (fludarabine, cytarabine, and granulocyte colony-stimulating factor), MXN/Ara-C (mitoxantrone and cytarabine), and HIDAC (high-dose cytarabine) (80.7% vs. 29.4%) ( 5 ). However, InO was not associated with a prolonged OS (7.7 months vs. 6.2 months) ( 6 , 7 ).…”